

# Report from Annual General Meeting in Oasmia Pharmaceutical AB

At the Annual General Meeting in Oasmia Pharmaceutical AB (the “company”) held on 27 May 2021, which due to the corona virus has been conducted solely through postal voting pursuant to temporary legislation, the following resolutions were passed. All resolutions were in accordance with the proposals described in detail in the general meeting documents which are available at the company’s website, [www.oasmia.com](http://www.oasmia.com). A statement in which the company’s Chief Executive Officer Francois Martelet comments on the company’s operations is available on the company’s website.

## **Adoption of the income statement and balance sheet**

It was resolved to adopt the income statement and balance sheet, as well as the consolidated income statement and consolidated balance sheet for the financial year 2020.

## **Resolution on dispositions in respect of the company’s result**

It was resolved that no dividend is paid and that available profits are carried forward.

## **Resolution on discharge from liability**

It was resolved to discharge all members of the Board of Directors and the Chief Executive Officer from liability for the financial year 2020.

## **Election of Board of Directors and auditor**

It was resolved that the number of members of the Board of Directors shall be five, without deputies. It was resolved on re-election Anders Härfstrand, Hege Hellström, Birgit Stattin Norinder and Peter Zonabend as well as new election of Andrea Buscaglia as members of the Board of Directors for the period until the end of the next Annual General Meeting. Anders Härfstrand was re-elected Chairman of the Board.

It was resolved that one registered accounting firm be elected as auditor, without deputies. It was resolved to re-elect the registered accounting firm KPMG AB as the company’s auditor for the period until the end of the next Annual General Meeting. The Authorized Public Accountant Duane Swanson will be appointed auditor in charge.

## **Resolution on fees to the Board of Directors and auditor**

It was resolved that the fees to the members of the Board of Directors shall be distributed as follows:

- SEK 500,000 to the Chairman of the Board and SEK 250,000 to each of the other Board members elected by the Annual General Meeting who are not employed by the company, and
- SEK 50,000 to the Chairman of the Audit Committee and SEK 25,000 to each of the other members of the Audit Committee, and SEK 50,000 to the Chairman of the Remuneration Committee and SEK 25,000 to each of the other members of the Remuneration Committee.

It was resolved that the auditor’s fees shall be paid as per approved invoice.

### **Resolution on principles for appointing a Nomination Committee and instructions for the Nomination Committee**

It was resolved to adopt principles for appointing a Nomination Committee prior to the Annual General Meeting in 2022 and instructions for the Nomination Committee's work.

### **Resolution on approval of remuneration report**

It was resolved to approve the Board of Directors' report regarding remuneration pursuant to Chapter 8, Section 53 a of the Swedish Companies Act.

### **Resolution on issue authorization**

It was resolved to authorize the Board of Directors to, on one or several occasions during the period up until the next Annual General Meeting, resolve on one or more issues of shares, warrants and/or convertible instruments. The Board of Directors shall be authorized to adopt decisions on an issue of shares, warrants and/or convertible instruments with or without deviation from the shareholders' pre-emption rights. The issue resolution may be an issue in kind or an issue by way of set-off and /or on such terms and conditions as referred to in Chapter 2, Section 5, second paragraph, points 1-3 and 5, of the Swedish Companies Act. The new shares, warrants and/or convertible instruments shall, in the event of a deviation from the shareholders' pre-emption rights, be issued at a subscription price based on the share price at the time of the issue (or in case of warrants or convertibles, with the share price as basis for a market valuation), decreased by any discount in line with market practice that the Board of Directors deems necessary. All other terms are decided by the Board of Directors, but shall be in line with market practice. A maximum of 89,673,909 shares, which corresponds to twenty percent of the total number of outstanding shares in the company at the time of the Annual General Meeting, may be issued under the authorization (including any new shares following the exercise or conversion of warrants and convertible instruments issued under the authorization).

### **For more information:**

Francois Martelet, Chief Executive Officer

Phone: 018-50 54 40

E-mail: [IR@oasmia.com](mailto:IR@oasmia.com)

### **About Oasmia Pharmaceutical AB**

Oasmia is a specialty pharma company dedicated to improving the lives of patients by enhancing the intravenous delivery of established and novel drugs in significant diseases, including cancer. Product development is based on Oasmia's proprietary drug delivery platforms which can be applied to medicines used in many therapeutic areas, to develop water soluble formulations of drugs that currently require chemical solubilizers for dissolution. The first product approved using this technology is Apealea® (paclitaxel micellar). Apealea has received market authorization in the European Union and several other territories for the treatment of first relapse in platinum-sensitive ovarian cancer, in combination with carboplatin. The Company is making Apealea accessible to patients through its partnership with Elevar Therapeutics, together with its existing commercial operations in the Nordic region. Oasmia's shares are traded on the Nasdaq Stockholm stock exchange (ticker: OASM). To find out more about Oasmia please visit [www.oasmia.com](http://www.oasmia.com).

### **Attachments**

---

[Report from Annual General Meeting in Oasmia Pharmaceutical AB](#)

---

